Lenacapavir for HIV Pre Exposure Prophylaxis

Join us for an essential discussion on Lenacapavir, the groundbreaking twice-yearly injectable recently approved by the FDA for HIV prevention.  With WHO guidelines expected to be released during the upcoming International AIDS Conference, this timely webinar will equip healthcare providers with essential knowledge about this powerful new tool in our mission to end the HIV epidemic.

2 CPDs are allocated per session